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Abstract
Background: The Wnt/β-catenin pathway has a key role in regulating cellular processes and its aberrant signaling
can lead to cancer development. The role of β-catenin expression in pancreatic ductal adenocarcinoma is somewhat
controversial. Transcription factor PROX1 is a target of Wnt/β-catenin signaling and it is involved in carcinogenesis
through alterations in its expression. The actions can be either oncogenic or tumor suppressive depending on the tissue.
The aim of this study was to investigate PROX1 and β-catenin expression in pancreatic ductal adenocarcinoma (PDAC).
Methods: Expression of PROX1 and β-catenin were evaluated in 156 patients by immunohistochemistry of tissue
microarrays. Associations between tumor marker expression and clinicopathological parameters were assessed by the
Fischer’s exact-test or the linear-by-linear association test. The Kaplan-Meier method and log-rank test were used for
survival analysis. Uni- and multivariate survival analyses were carried out by the Cox regression proportional hazard model.
Results: High PROX1 expression was seen in 74 (48 %) tumors, and high β-catenin expression in 100 (65 %). High
β-catenin expression was associated with lower tumor grade (p = 0.025). High PROX1 and β-catenin expression
associated significantly with lower risk of death from PDAC in multivariate analysis (HR = 0.63; 95 % CI 0.42–0.95,
p = 0.026; and HR = 0.54; 95 % CI 0.35–0.82, p = 0.004; respectively). The combined high expression of PROX1 and
β-catenin also predicted lower risk of death from PDAC (HR = 0.46; 95 % CI 0.28–0.76, p = 0.002).
Conclusion: In conclusion, high PROX1 and β-catenin expression were independent factors for better prognosis
in pancreatic ductal adenocarcinoma.
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Background
The Wnt/β-catenin signaling pathway has a role in regu-
lating cellular processes including organ development
and differentiation, and tissue homeostasis in adults [1].
It is widely established that its aberrant signaling can
lead to cancer development [2]. β-catenin is a key
molecule in this pathway. It is an intracellular protein
that is localized in cell membrane, cytoplasm and nu-
cleus. The binding of Wnt ligand to its receptors inhibits
β-catenin phosphorylation, which allows β-catenin to es-
cape from degradation. It accumulates in the cytoplasm,
and translocates to the nucleus. After localizing to the
nucleus, β-catenin activates a target gene expression
through interacting mainly with members of the T-cell
factor/lymphoid enhancer factor (TCF/LEF) family of
transcription factors (as reviewed in [3, 4]). In colorectal
cancer (CRC), most tumors have a mutation in a key
regulatory factor of the Wnt/β-catenin pathway. Often
the mutation is in adenomatous polyposis coli (APC) or
protein β-catenin encoding gene (CTNNB1), which re-
sults in activation of the pathway [3].
In pancreatic ductal adenocarcinoma (PDAC), the role
of the Wnt/β-catenin signaling pathway is controversial
because of the variable and sometimes paradoxical effects
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in the pancreas. PDAC is a genetically heterogenous
cancer with several key mutated genes including KRAS2,
CDKN2A/p16, SMAD4/DPC4, and TP53 [5]. Although
genetic alterations of the Wnt signaling pathway are
involved in PDAC tumors [6], mutations of APC or
CTNNB1 are less common [7]. Heiser et al. showed in
mice that by introducing a β-catenin stabilizing mutation
in CTNNB1 leads to pancreatic hypoplasia at an early
phase of the developing pancreas. If this mutation is intro-
duced in later phase in the developing pancreas, it results
in enlargement of the exocrine pancreas without tumor
formation [8].
An immunohistochemically positive expression of β-
catenin has been reported earlier, but the results have
remained somewhat controversial. Lowy et al. noted re-
duced membranous expression of β-catenin in PDAC
correlating with loss of tumor differentiation [9]. How-
ever, there is evidence that the Wnt/β-catenin signaling
pathway is upregulated in PDAC both by immunohisto-
chemistry and polymerase chain reaction [7, 10]. So far,
the prognostic significance of β-catenin expression in
PDAC has been investigated in a few studies with rather
short follow-up times [11–14].
The transcription factor PROX1 has been shown to be
a downstream target of the Wnt/β-catenin/TCF pathway
in colorectal tumor neoplastic transformation and pro-
gression [15]. PROX1 is a transcriptional regulator and a
part of the homeobox transcription factor family [16]. It
has a key role in the development of the central nervous
system [17], lens [18], liver [19], pancreas [19], lymphatic
system [20], and heart [21]. But in addition, it is involved
in oncogenesis through alterations in its expression.
Depending on the tissue it can act either as a tumor sup-
pressor or as an oncogene [22].
Recently, Wiener et al. constituted that PROX1 func-
tions as a stem cell regulator in intestinal adenomas and
in CRC, but not in the normal intestine [23]. In high-
grade gliomas, and in colorectal cancer, high PROX1
tissue expression is associated with poor patient survival
[24]. In esophageal squamous cell carcinoma PROX1
mediates the anti-proliferative effect by IFN-γ [25]. In
hematological malignancies and in breast cancer PROX1
expression has been shown to be decreased [26, 27]. In
hepatocellular carcinoma, depletion of PROX1 causes a
significant increase in cell proliferation, and patients with
high PROX1 expression have better prognosis compared
to patients with low expression [28]. Schneider et al.
showed that PROX1 is less expressed in pancreatic cancer
cells than in the normal exocrine pancreas [29]. They also
noticed that the gene expression level of PROX1 was
lower in patients who survived less than 6 months than in
patients with longer survival [29]. However, to our know-
ledge, immunohistochemical prognostic studies of PROX1
tissue expression are lacking in PDAC.
The aim of this study was to examine tumor expression
and prognostic value of PROX1 and β-catenin in PDAC.
Methods
Patients
This study is based on a series of 189 consecutive PDAC
patients surgically treated in 2000–2011 at the Department
of Surgery, Helsinki University Hospital. Only patients with
verified PDAC were included in this study. Median age at
operation was 64 (range 39–84) years. Twenty-one patients,
who received neoadjuvant chemotherapy, were excluded
from the study. Eight patients were eventually diagnosed
with stage IV disease with distant metastases according to
the American Joint Committee on Cancer Pancreatic
Cancer Staging System [30], and four patients lacked data
on stage. They were excluded from the study. Altogether,
156 patients were included in the study. Patients’ records,
the Finnish Population Registry and Statistics Finland were
used to obtain survival data and cause of death of the
patients. A description of the study cohort is in Table 5.
Preparation of tumor tissue microarrays and
immunohistochemistry
Formalin-fixed and paraffin-embedded surgical tissue
samples were collected from the archives of the Depart-
ment of Pathology, Helsinki University Hospital. Experi-
enced pathologists (J.H. and S.N.) re-evaluated all samples
for confirmation of the histopathological diagnosis of
PDAC. Representative regions of tumor specimens were
defined and tumor areas were marked on hematoxylin-
and eosin-stained tumor slides for preparation of tissue
microarray blocks (TMA). Two 1.0-mm cores were taken
from each tumor block with a semiautomatic tissue
microarrayer (Tissue Arrayer 1, Beecher Instruments Inc.,
Silver Spring, MD, USA). In order to evaluate TMA repre-
sentativeness compared to whole tissue blocks, we exam-
ined altogether six spots per patient taken from different
areas/parts of the tumor.
TMA blocks were freshly cut into 4-μm sections. After
deparaffinization in xylene and rehydration through a grad-
ually decreasing concentration of ethanol to distilled water,
slides were treated in a PreTreatment module (Lab Vision
Corp., Fremont, CA, USA) in Tris–HCl (pH 8.5) and Tris-
EDTA (pH 9) buffer for 20 min at 98 °C for antigen re-
trieval. Staining of sections was performed in an Autostai-
ner 480 (Lab Vision Corp., Fremont, CA, USA) by the
Dako REAL EnVision Detection system, Peroxidase/DAB
+, Rabbit/Mouse (Dako, Glostrup, Denmark) for β-catenin,
and by ImmPRESS HRP Polymer Detection Kit, Peroxid-
ase, Anti-Goat IgG (Vector Laboratories, Burlingame, CA,
USA) for PROX1. Tissues were incubated with beta-
Catenin Antibody (Invitrogen, Thermo Fisher Scientific,
Inc., Waltham, MA, USA; diluted to 1:500 = 5 μg/ml) for
one hour at room temperature, and with Anti-human
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Prox1 Antibody (R&D Systems, Inc., Minneapolis, MN,
USA; diluted to 1:1500 = 15 μg/ml) for overnight at room
temperature. Samples of colon tissue and normal lymph
node served as positive controls in each staining series (see
Additional files 1 and 2). We also chose 13 whole tumor
tissue blocks and corresponding lymph node metastases
from the patient cohort to compare PROX1 expression in
the tumor and its lymph node metastases.
Evaluation of stainings
Cytoplasmic stainings of PROX1 and β-catenin were scored
as negative (0), weakly positive (1), moderately positive (2),
or strongly positive (3) according to staining intensity. Also,
β-catenin membranous staining was evaluated. In the sam-
ples, where no membranous staining was seen, there was
no cytoplasmic staining either. The highest score of each
sample was considered representative for analysis. Scoring
was performed by two independent investigators (K.S. and
J.H.) without knowledge of clinical data and outcome. In
case of differing scores, consensus score was discussed and
determined.
Statistical analyses
Categories of β-catenin and PROX1 were dichotomized
for statistical purposes into low (scores 0–1) and high
(scores 2–3). A three-class categorization was created to
study these two tumor markers together: low (PROX1,
and β-catenin low), moderate (either PROX1, or β-
catenin high), and high (PROX1, and β-catenin high).
Associations between tumor marker expression and clin-
icopathological parameters were assessed by the Fischer’s
exact-test or the linear-by-linear association test. The
Kaplan-Meier method and log-rank test were used for
survival analysis. The Bonferroni correction was used for
multiple comparisons by dividing the probability level by
the number of comparisons. The Spearman correlation
coefficient with bootstrapped (1000 resamples, bias cor-
rected) confidence intervals was calculated to find out
correlations between PROX1 and β-catenin expression.
Uni- and multivariate survival analyses were carried out by
the Cox regression proportional hazard model adjusted for
age, gender, stage, metastasized lymph node ratio (LNR)
≥/<20 % (cut-off ≥/<20 %), perivascular invasion, and post-
operative adjuvant therapy. Since stage and LNR are
internally correlated to each other, a combination variable
was formed for multivariate analyses (see Table 6). Inter-
action terms were considered. The Cox model assumption
of constant hazard ratios over time was tested. For each
testable variable at a time, a time-dependent covariate was
included separately. All variables fulfilled the assumption.
Stage and lymph node ratio were combined into a single
variable to simplify the model. A p-value <0.05 was consid-
ered significant and all tests were two-sided. Statistical ana-
lyses were computed with SPSS version 22.0 (IBM SPSS
Statistics, version 22.0 for Windows/MAC; SPSS, Inc.,
Chicago, IL, USA, an IBM Company).
Results
Immunohistochemical staining
PROX1 expression was cytoplasmic and evenly distrib-
uted with no distinctive membranous staining. Cytoplas-
mic staining was scored as described above. In normal
pancreatic tissue apparent nuclear staining is present
although all the nuclei are not stained. In two cancer
tissue samples we saw staining of the nuclei, and the
cytoplasmic staining scores in these samples were 1, and
3. In all the other cancer specimens nuclei were nega-
tive. In the whole tumor specimens, there was no nu-
clear staining in the metastases; only negative or weak
cytoplasmic staining was present (Fig. 1).
β-catenin expression was distributed in the cell mem-
brane and within the cytoplasm. Only in a few exceptions
the staining was not uniform throughout the cell. With
more intense membranous staining, also cytoplasmic
staining was stronger. The cytoplasmic expression pattern
showed two different types of staining; homogenous and
granular. There was no distinct nuclear staining. Only
three samples lacked membranous staining (Fig. 2). The
membranous and cytoplasmic staining were very difficult
to score separately. Because of this, cytoplasmic expres-
sion was used in statistical analyses.
PROX1 staining could be evaluated in 154 (99 %)
specimens: 20 (13 %) showing negative, 60 (39 %) weak,
66 moderate, (43 %) and 8 (5 %) strong staining (Fig. 3).
β-catenin cytoplasmic staining could be evaluated in 153
(98 %) specimens: 1 (1 %) showing negative, 52 (34 %)
weak, 63 (41 %) moderate, and 37 (24 %) strong staining
(Fig. 4). Combined PROX1 and β-catenin expression was
evaluated in 152 (97 %) tumors: 38 (25 %) low, 56 (37 %)
moderate, and 58 (38 %) high expression pattern.
Association between PROX1 and β-catenin expression
and clinicopathological variables
There was a statistically significant association between
PROX1 expression and age; patients in the low PROX1
expression group were younger than in the high PROX1
expression group (p = 0.038). PROX1 expression did not
correlate with gender, stage, LNR, histological grade,
perineural, or perivascular invasion (Table 1).
Patients with low β-catenin expression showed a sig-
nificant association with higher tumor histological grade
compared to patients with high expression (p = 0.025).
No significant association was found between β-catenin
and age, gender, stage, LNR, perineural, or perivascular
invasion (Table 2).
There was no correlation between combined PROX1
and β-catenin expression and age, gender, stage, histo-
logical grade, LNR, perineural, or perivascular invasion
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(Table 3). PROX1 and β-catenin expression correlated
with each other (Spearman correlation coefficient = 0,371;
95 % CI 0.24–0.50; p < 0.001).
Survival analysis
Five-year cancer-specific survival (CSS) was not signifi-
cantly different for PDAC patients with low PROX1 expres-
sion compared to those with high expression (log-rank,
p = 0.174, Fig. 5). Five-year CSS was 15.5 % (95 % CI
6.7–24.3 %) for patients with low PROX1 expression,
and 20.0 % (95 % CI 9.2–30.8 %) when PROX1 expression
was high (Table 4). PDAC patients with low β-catenin
expression showed significantly poorer CSS than those pa-
tients with high expression (log-rank, p = 0.007, Fig. 6).
Five-year CSS for PDAC patients with low β-catenin
expression was 11.3 % (95 % CI 2.1–20.5 %), and 22.4 %
Fig. 1 Immunohistochemical staining pattern of PROX1 in normal pancreas, in pancreatic ductal adenocarcinoma (PDAC), and in metastasized
lymph node. a PROX1 staining pattern in normal pancreatic tissue. Distinct nuclear positivity to be seen. b PROX1 staining pattern in transitional
zone of normal pancreas and cancerous tissue (arrowhead). c and d PROX1 staining pattern in metastasized lymph node. No nuclear expression
in cancer cells. Original magnification × 200 in (a, b, and d). Original magnification × 100 in C
Fig. 2 Immunohistochemical staining pattern of β-catenin in normal pancreas and in pancreatic ductal adenocarcinoma (PDAC). a β-catenin expression
pattern in normal pancreatic tissue. Distinct membranous staining to be seen. b Weak cytoplasmic β-catenin expression positivity in PDAC
with no membranous positivity. c Weak cytoplasmic β-catenin expression positivity in PDAC with some membranous positivity. d Moderate
cytoplasmic β-catenin expression positivity in PDAC with distinct granular appearance. Original magnification × 400
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(95 % CI 13.0–31.8 %) for those with high expression
(Table 4).
Combined expression of PROX1 and β-catenin showed
significantly poorer CSS for PDAC patients with low com-
pared to high expression (p = 0.013). Between patients
with moderate and low expression (p = 0.092), or with
moderate and high expression (p = 0.435) no significant
difference in CSS was seen (Fig. 7). Five-year CSS for pa-
tients with low combined expression was 10.3 % (95 % CI
−0.7–21.3 %), with moderate combined expression 18.7 %
(95 % CI 9.9–29.5 %), and with high combined expression
21.3 % (95 % CI 8.1–34.5 %) (Table 4).
In univariate analyses high β-catenin expression associ-
ated significantly with lower risk of death from PDAC
(HR = 0.61, 95 % CI 0.42–0.88; p = 0.008). High PROX1
expression seemed to reduce the risk of death from
PDAC, but this result just failed to be statistically signifi-
cant in univariate analysis (HR = 0.71, 95 % CI 0.49–1.01;
p = 0.053). With PROX1 and β-catenin, combined high
expression showed lower risk of death from PDAC
(HR = 0.52, 95 % CI 0.33–0.83; p = 0.006). With moder-
ate combined expression the risk of death from PDAC
was not statistically significant (HR = 0.69, 95 % CI
0.44–1.08; p = 0.103). Other prognostic variables in
Fig. 3 Immunohistochemical staining pattern of PROX1 in pancreatic ductal adenocarcinoma (PDAC). Representative images of PROX1 expression
in PDAC. a negative, b weak, c moderate, and d strong cytoplasmic positivity without staining of the nuclei. Original magnification × 400
Fig. 4 Immunohistochemical staining pattern of β-catenin in pancreatic ductal adenocarcinoma (PDAC). Representative images of β-catenin expression
in PDAC. a negative cytoplasmic, b weak cytoplasmic and membranous positivity, c moderate cytoplasmic, and d strong cytoplasmic and positive
membranous positivity. Original magnification × 400
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univariate analyses were stage, lymph node positivity,
perivascular invasion, and postoperative adjuvant the-
rapy (Table 5).
In multivariate analyses adjusted for age, gender, stage,
LNR, perivascular invasion, and adjuvant therapy high
β-catenin expression remained statistically significant for
Table 1 Association of clinicopathological parameters and
PROX1 expression
PROX1 expression
Low (0–1) High (2–3)
n(%) 80 (51.9) 74 (48.1) p-value
Age, years
< 65 46 (57.5) 30 (40.5) 0.038
≥ 65 34 (42.5) 44 (59.5)
Gender
Male 45 (56.3) 40 (54.1) 0.871
Female 35 (43.7) 34 (45.9)
T
1 5 (6.3) 7 (9.5) 0.274
2 18 (22.5) 22 (29.7)
3 56 (70.0) 43 (58.1)
4 1 (1.3) 2 (2.7)
N
0 23 (28.8) 25 (33.8) 0.602
1 57 (71.2) 49 (66.2)
Stage (WHO)
IA 4 (5.0) 5 (6.8) 0.550
IB 8 (10.0) 10 (13.5)
IIA 11 (13.8) 9 (12.2)
IIB 56 (70.0) 48 (64.9)
III 1 (1.3) 2 (2.7)
Lymph node ratio
< 20 % 57 (71.3) 60 (83.3) 0.086
≥ 20 % 23 (28.7) 12 (16.7)
Missing 2
Grade
1 10 (14.7) 12 (19.0) 0.543
2 47 (69.1) 42 (66.7)
3 11 (16.2) 9 (14.3)
Missing 12 11
Perineural invasion
Yes 49 (73.1) 51 (82.3) 0.291
No 18 (26.9) 11 (17.7)
Missing 13 12
Perivascular invasion
Yes 24 (36.9) 19 (32.2) 0.706
No 41 (63.1) 40 (67.8)
Missing 15 15
Fischer exact-test was used for 2×2 tables and linear-by-linear association test
for tables with more than two rows. Missing data excluded from the analyses
Table 2 Association of clinicopathological parameters and
β-catenin expression
β-catenin expression
Low (0–1) High (2–3)
n(%) 53 (34.6) 100 (65.4) p-value
Age, years
< 65 28 (52.8) 48 (48.0) 0.613
≥ 65 25 (47.2) 52 (52.0)
Gender
Male 32 (60.4) 52 (52.0) 0.394
Female 21 (39.6) 48 (48.0)
T
1 3 (5.7) 8 (8.0) 0.602
2 14 (26.4) 26 (26.0)
3 34 (64.2) 65 (65.0)
4 2 (3.8) 1 (1.0)
N
0 15 (28.3) 32 (32.0) 0.714
1 38 (71.7) 68 (68.0)
Stage (WHO)
IA 3 (5.7) 6 (6.0) 0.590
IB 6 (11.3) 12 (12.0)
IIA 5 (9.4) 14 (14.0)
IIB 37 (69.8) 67 (67.0)
III 2 (3.8) 1 (1.0)
Lymph node ratio
< 20 % 40 (75.5) 77 (78.6) 0.687
≥ 20 % 13 (24.5) 21 (21.4)
Missing 2
Grade
1 5 (10.9) 17 (19.8) 0.025
2 29 (63.0) 60 (69.8)
3 12 (26.1) 9 (10.5)
Missing 7 14
Perineural invasion
Yes 34 (77.3) 66 (77.6) 1.000
No 10 (22.7) 19 (22.4)
Missing 9 15
Perivascular invasion
Yes 19 (43.2) 24 (30.0) 0.169
No 25 (56.8) 56 (70.0)
Missing 9 20
Fischer exact-test was used for 2×2 tables and linear-by-linear association test
for tables with more than two rows. Missing data excluded from the analyses
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better prognosis (HR = 0.54, 95 % CI 0.35–0.82; p =
0.004), and high PROX1 expression was also statistically
significant (HR 0.63, 95 % CI 0.42–0.95; p = 0.026). The
combined high expression of β-catenin and PROX1
remained statistically significant (HR 0.46, 95 % CI 0.28–
0.76; p = 0.002) (Table 6).
Discussion
We here show that high tissue expression of PROX1 and
β-catenin independently predict better prognosis in PDAC.
PROX1 expression is vital for pancreatic development.
Loss of PROX1 in the pancreas leads to remarkable size
reduction [31], and premature acinar cell differentiation
and increased ductal cell proliferation [32]. Schneider et
al. reported in 2006 that pancreatic cancer cells express
less PROX1 mRNA than normal exocrine pancreatic cells
[29]. They noticed that PROX1 gene expression levels
were lower in patients with survival less than 6 months.
Our study shows a similar tendency by immunohisto-
chemistry although the difference in survival was not sig-
nificant. To our knowledge, no prognostic studies on
PROX1 protein expression in PDAC have been reported
so far.
Increased PROX1 expression has been discovered to be
associated with poor prognosis in CRC although it was
not an independent prognostic factor in multivariate ana-
lysis [33]. These results are opposite to our results in
PDAC. In CRC, high PROX1 expression was associated
with high tumor grade. This finding was not confirmed in
our study. PROX1 is required for the formation of lymph-
atic vasculature [20], and overexpression of PROX1 in
blood endothelial cells induces lymphatic endothelial cell
gene expression [34]. However, Schneider et al. suggested
that active lymphangiogenesis is not needed for lympho-
vascular spread in pancreatic cancer [30]. Recent data
shows that positive PROX1 expression correlates with
positive lymph node metastases in CRC and gastric cancer
[35, 36]. It remains unclear whether the downregulation
of PROX1 expression enhances the lymphatic metastatic
spread of pancreatic ductal adenocarcinoma.
We evaluated the staining of PROX1 in the cytoplasm,
whereas in the previous studies of CRC, hepatocellular
carcinoma (HCC), and gliomas, only the staining in
tumor cell nuclei were evaluated [24, 28, 33]. In a recent
study of gastric cancer, also cytoplasmic PROX1 expres-
sion by IHC was evaluated and it correlated with mRNA
amplification [37]. We noted nuclear staining only in
two tumor specimens. However, nuclear staining is
present in the normal pancreas. At some point, the nu-
clear expression decreases, and in cancerous tissue, only
cytoplasmic expression is left. These findings suggest
that PROX1 may not function as an active transcription
factor in PDAC. The role of cytoplasmic PROX1 expres-
sion has been studied in papillary thyroid cancer (PTC) by
Choi et al. [38]. They discovered that PROX1 becomes
inactivated through mRNA downregulation by aberrant
NOTCH signaling, and cytoplasmic mislocalization of
PROX1 increases protein stability in PTC cells. In addition,
Table 3 Association of clinicopathological parameters and
β-catenin and PROX1 expression combined
Low Moderate High
n (%) 38 (25.0) 56 (36.8) 58 (38.2) p-value
Age, years
< 65 21 (55.3) 32 (57.1) 23 (39.7) 0.121
≥ 65 17 (44.7) 24 (42.9) 35 (60.3)
Gender
Male 23 (60.5) 31 (55.4) 30 (51.7) 0.409
Female 15 (39.5) 25 (44.6) 28 (48.3)
T
1 2 (5.3) 4 (7.1) 5 (8.6) 0.343
2 10 (26.3) 12 (21.4) 18 (31.0)
3 25 (65.8) 39 (69.6) 34 (58.6)
4 1 (2.6) 1 (1.8) 1 (1.7)
N
0 10 (26.3) 17 (30.4) 20 (34.5) 0.436
1 28 (73.7) 39 (69.6) 38 (65.5)
Stage (WHO)
IA 2 (5.3) 3 (5.4) 4 (6.9) 0.412
IB 4 (10.5) 6 (10.7) 8 (13.8)
IIA 4 (10.5) 7 (12.5) 8 (13.8)
IIB 27 (71.1) 39 (69.6) 37 (63.8)
III 1 (2.6) 1 (1.8) 1 (1.7)
Lymph node ratio
< 20 % 29 (76.3) 38 (67.9) 49 (87.5) 0.138
≥ 20 % 9 (23.7) 18 (32.1) 7 (12.5)
Missing 2
Grade
1 4 (12.5) 7 (14.0) 11 (22.4) 0.059
2 20 (62.5) 36 (72.0) 33 (67.3)
3 8 (25.0) 7 (14.0) 5 (10.2)
Missing 6 6 9
Perineural invasion
Yes 25 (73.5) 32 (76.2) 42 (80.8) 0.438
No 9 (26.5) 10 (23.8) 10 (19.2)
Missing 4 14 6
Perivascular invasion
Yes 13 (38.2) 17 (42.5) 13 (26.5) 0.247
No 21 (61.8) 23 (57.5) 36 (73.5)
Missing 4 16 9
Linear-by-linear association test was used here
Saukkonen et al. BMC Cancer  (2016) 16:472 Page 7 of 12
restoration of PROX1 impaired tumor formation and di-
minished invasiveness of PTC cells.
Whether the downexpression in the nuclei results
from the evolved pancreatic cancer, or results in pancre-
atic cancer formation, remains unknown. Because of the
limitations of IHC, we can only speculate, whether cyto-
plasmic PROX1 in pancreatic tumor tissue is in active or
inactive form. The main remaining question is what the
role of cytoplasmic PROX1 expression is and what the
signal is that leads to relocation to the cytoplasm [38].
This question needs further studies to clarify the role of
cytoplasmic PROX1 expression in PDAC. Our results
are in line with the findings of PROX1 expression earlier
discovered in PDAC, but also show the different nature
of CRC and PDAC.
In the normal pancreas β-catenin expression is pre-
dominantly localized in the membrane of ductal cells.
In pancreatic cancer, down-regulation of membrane
expression and increased cytoplasmic expression are
seen [11–14]. In our series, mainly uniform, granular
cytoplasmic and membranous staining were seen, but
there were only three specimens lacking membranous
staining.
A few studies have reported that reduced or abnormal
membranous β-catenin expression predicts poor prognosis
of PDAC patients [11, 13]. Wang et al. found no prognostic
impact of β-catenin cytoplasmic expression in PDAC [14].
Qiao et al. showed that reduced membranous and positive
cytoplasmic expression of β-catenin associated with poorer
survival in PDAC during one-year follow-up [12]. These
results differ from ours but the follow-up times in previous
studies are only one or two years, and the patient cohorts
have been small (n = 43–48). In none of those studies
nuclear positivity was reported. In a few studies re-
duced β-catenin expression correlated with tumor de-
differentiation, but the prognostic significance was not
investigated [9, 39]. However, the controversy remains
as in gene array analysis it has been demonstrated, that
inhibition of Wnt/β-catenin signaling pathway blocks
proliferation and induces apoptosis of cultured PDAC
cells [10]. Also, increased β-catenin expression and pro-
tein levels have been reported in pancreatic tumors [7].
There is a need for further studies to validate the role
Fig. 5 Low PROX1 expression suggests a poor prognosis in pancreatic ductal adenocarcinoma. Cancer-specific survival analysis according to the
Kaplan-Meier method for PROX1 expression in pancreatic ductal adenocarcinoma
Table 4 Cancer-specific survival (CSS) for pancreatic ductal
adenocarcinoma patients by PROX1 and β-catenin expression
Five-year CSS Two-year CSS
CSS (%) 95 % CI CSS (%) 95 % CI
PROX1 expression
Low 15.5 6.7–24.3 43.4 32.2–54.6
High 20.0 9.2–30.8 60.2 49.8–71.6
β-catenin expression
Low 11.3 2.1–20.5 33.1 20.1–46.1
High 22.4 13.0–31.8 61.6 51.8–71.4
Combined expression
Low 10.3 −0.7–21.3 33.2 17.6–48.8
Moderate 18.7 9.9–29.5 48.2 34.8–61.6
High 21.3 8.1–34.5 66.7 54.3–79.1
Abbrevations: CSS cancer-specific survival, CI confidence interval. Combined
expression refers to combined expression of PROX1 and β-catenin
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of β-catenin expression in PDAC as reviewed by Morris
et al. [40]. Our study shows by IHC that β-catenin ex-
pression in PDAC is both membranous and cytoplasmic
with no distinct nuclear staining, and high β-catenin
expression predicts better prognosis.
The combination of PROX1 and β-catenin expression
was created, because they have been linked to the same
signaling pathway and their activation/expression is in-
creased in CRC [15, 23, 33]. Furthermore, Yu et al. showed
recently in CRC that β-catenin-PROX1 signaling axis is
regulated by a transcriptional coactivator deleted in breast
cancer (DBC1) [41]. They concluded that DBC1 acts as a
positive regulator and as a key factor of β-catenin-PROX1
signaling axis in CRC progression. We demonstrate by
Fig. 6 Low β-catenin expression is a marker of poor prognosis in pancreatic ductal adenocarcinoma. Cancer-specific survival analysis according to
the Kaplan-Meier method for β-catenin expression in pancreatic ductal adenocarcinoma
Fig. 7 Concomitant positivity by β-catenin and PROX1. Cancer-specific survival analysis according to the Kaplan-Meier method for combined expression
of β-catenin and PROX1. A categorization of three classes was created to study the two markers together: low (β-catenin, and PROX1, low), moderate
(either β-catenin, or PROX1 high), and high (β-catenin, and PROX1 high)
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IHC that both PROX1 and β-catenin expression are de-
creased in PDAC patients, and their expression are cor-
related significantly. These results were opposite from
those in CRC. Whether β-catenin and PROX1 function
in the same, yet opposite, way, remains unclear. How-
ever, we did not find any significant prognostic effect
with combined PROX1 and β-catenin expression com-
pared to β-catenin expression alone. Further analyses
are required to examine the activity of Wnt/β-catenin/
PROX1 signaling pathway in PDAC. In order to thor-
oughly analyze the effect of PROX1 and β-catenin IHC
expression on prognosis, a multi-center study with lar-
ger patient cohorts would be needed.
The TMA technique allows analysis of large patient
cohorts. On the other hand, smaller areas of the tumors
are evaluated compared to whole tissue sections. By tak-
ing cores from different parts of the tumor, possible
sampling error can be diminished. Only less than 2 % of
the specimens were lost in this patient cohort because of
technical reasons. The strength of this study is a quite
large patient cohort with long follow-up time. Unfortu-
nately, due to the long period of data collecting, some of
the crucial clinicopathological parameters were not
available. Also, one of the weaknesses of the study is the
lack of knowledge of the reliable resection margin status
(R0/R1), which is known to be an important prognostic
factor [42]. This results from the fact that our study is
retrospective, and only in the last few years clinicians
and pathologists have drawn enough attention to this
important matter. All histological specimens were re-
evaluated and only ductal adenocarcinomas were in-
cluded in the study.
Table 5 Cox univariate analysis of relative risk of death from
pancreatic ductal adenocarcinoma by β-catenin and PROX1
expression (n = 156)
Covariate n HR 95 % CI p-value
PROX1 expression
Low 80 1.00 1.000
High 74 0.70 0.49–1.00 0.053
Missing 2
β-catenin expression
Low 53 1.00 1.000
High 100 0.61 0.42–0.88 0.008
Missing 3
Combined PROX1 and β-catenin expression
Low 38 1.00 1.000
Moderate 56 0.69 0.22–1.01 0.103
High 58 0.52 0.33–0.83 0.006
Missing 4
Age at operation
< 65 77 1.00 1.000
≥ 65 79 1.06 0.74–1.50 0.752
Gender
Male 86 1.00 1.000
Female 70 0.93 0.65–1.32 0.668
T
1 12 1.00 1.000
2 40 1.02 0.47–2.24 0.957
3 101 1.65 0.80–3.41 0.178
4 3 4.09 1.07–15.66 0.040
N
0 48 1.00 1.000
1 108 1.80 1.20–2.70 0.004
Grade
1 22 1.00 1.000
2 90 1.14 0.66–1.96 0.644
3 21 2.05 1.04–4.02 0.038
Missing 23
Stage
IA, and IB 27 1.00 1.000
IIA, and IIB 126 2.01 1.19–3.41 0.009
III 3 5.23 1.49–18.34 0.010
Stage and LNR
IA, IB, and IIA 47 1.00 1.000
IIB, III and LNR <20 % 73 1.50 0.97–2.31 0.071
IIB, III and LNR >20 % 36 3.12 1.91–5.11 <0.001
Table 5 Cox univariate analysis of relative risk of death from
pancreatic ductal adenocarcinoma by β-catenin and PROX1
expression (n = 156) (Continued)
Perivascular invasion
No 43 1.00 1.000
Yes 83 1.89 1.27–2.83 0.002
Missing 30
Perineural invasion
No 30 1.00 1.000
Yes 101 1.44 0.90–2.31 0.126
Missing 25
Postoperative adjuvant therapy
No 75 1.00 1.000
Yes 79 0.65 0.45–0.92 0.016
Missing 2
Abbreviations: HR hazard ratio, CI confidence interval, LNR metastasized lymph
node ratio. Stage and LNR covariate was formed to cover both in
multivariate analysis
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Conclusion
We show that high tissue expression of PROX1 and β-
catenin, both independently, predict better prognosis
in PDAC. PROX1 expression is not seen in the nuclei
of PDAC cells, but in the cytoplasm. β-catenin expres-
sion localizes both to the cytoplasm and to the cell
membrane. To our knowledge, this is the first report
on the prognostic value of PROX1 protein expression
in PDAC.
Additional files
Additional file 1: Positive control of immunohistochemical expression
of PROX1 in colon tissue. (TIF 3631 kb)
Additional file 2: Positive control of immunohistochemical expression
of β-catenin in colon tissue. (TIF 3631 kb)
Abbreviations
APC, adenomatous polyposis coli; CI, confidence interval; CRC, colorectal
cancer; CSS, cancer-specific survival; CTNNB1, protein β-catenin encoding
gene; DBC1, deleted in breast cancer; HCC, hepatocellular carcinoma; HR,
hazard ratio; IFN-γ, interferone γ; IHC, immunohistochemistry; LNR, lymph
node ratio; PDAC, pancreatic ductal adenocarcinoma; PROX1, prospero
homeobox protein 1; PTC, papillary thyroid cancer; TCF/LEF, T-cell factor/
lymphoid enhancer factor; TMA, tissue microarray
Acknowledgements
We thank Päivi Peltokangas, Eveliina Markkula, and Elina Aspiala for their
excellent technical assistance.
Funding
This study was supported by grants from Finska Läkaresällskapet, The Sigrid
Juselius Foundation, The Finnish Cancer Foundation, Georg and Mary Ehrnrooth
Foundation, Kurt och Doris Palander Foundation, K. Albin Johansson Foundation,
and The Finnish Medical Foundation.
Availability of data and materials
All relevant data and materials are included in the manuscript. For the full
detailed data, please contact the corresponding author.
Authors’ contributions
KS scored the immunohistochemical stainings, performed the statistical
analyses, participated in data collection, and drafted the manuscript. JH was
responsible for scoring of the stainings, for stamping the slides for the TMA.
HM was responsible for statistical analyses. AJ participated in data collection.
SN was responsible for histology re-evaluation. PK and KA helped to draft
the manuscript. HS was responsible for data collection, and helped to draft
the manuscript. CH planned the study, was responsible for methods, and helped
to draft the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study complies with the declaration of Helsinki and was approved by
the Surgical Ethics Committee of Helsinki University Hospital (Dnro HUS 226/
E6/06, extension TMK02 §66 17.4.2013), and the National Supervisory
Authority of Welfare and Health (Valvira Dnro 10041/06.01.03.01/2012).
Written informed consent was given by participants for their clinical
records to be used in this study.
Author details
1Department of Surgery, University of Helsinki and Helsinki University
Hospital, P.O. Box 440FIN-00029 HUS Helsinki, Finland. 2Research Programs
Unit, Translational Cancer Biology, University of Helsinki, P.O. Box 63, Helsinki
FIN-00014, Finland. 3Department of Pathology, Haartman Institute and
HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki
FIN-00014, Finland.
Received: 25 February 2016 Accepted: 28 June 2016
References
1. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human
disease. J Invest Dermatol. 2009;129(7):1614–27. Nature Publishing Group.
2. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin
signalling: diseases and therapies. Nat Rev Genet. 2004;5(9):691–701. Nature
Publishing Group.
3. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling
in gastrointestinal cancers. Gastroenterology. 2012;142(2):219–32.
4. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in
malignant progression of cancer. Cancer Metastasis Rev. 2009;28(1–2):151–66.
Springer US.
5. Hong S-M, Park JY, Hruban RH, Goggins M. Molecular signatures of pancreatic
cancer. Arch Pathol Lab Med. 2011;135(6):716–27.
6. Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, et al. Core
signaling pathways in human pancreatic cancers revealed by global
genomic analyses. Science. 2008;321(5897):1801–6. American Association for
the Advancement of Science.
7. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, et al. Aberrant
Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia. 2006;
8(4):279–89.
8. Heiser PW, Lau J, Taketo MM, Herrera PL, Hebrok M. Stabilization of beta-
catenin impacts pancreas growth. Development. 2006;133(10):2023–32. The
Company of Biologists Ltd.
9. Lowy AM, Fenoglio-Preiser C, Kim OJ, Kordich J, Gomez A, Knight J,
et al. Dysregulation of beta-catenin expression correlates with tumor
differentiation in pancreatic duct adenocarcinoma. Ann Surg Oncol.
2003;10(3):284–90.
10. Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJA,
Deramaudt T, et al. Common activation of canonical Wnt signaling in
pancreatic adenocarcinoma. PLoS ONE. 2007;2(11):e1155. Hatakeyama M,
editor. Public Library of Science.
11. Li Y-J, Wei Z-M, Meng Y-X, Ji X-R. Beta-catenin up-regulates the expression
of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships
with carcinogenesis and metastasis. World J Gastroenterol. 2005;11(14):
2117–23. Baishideng Publishing Group Inc.
Table 6 Cox multivariate analysis of relative risk of death from pancreatic ductal adenocarcinoma by β-catenin and PROX1 expression
β-catenin PROX1 Combined
β-catenin expression HR (95 % CI) P-value PROX1 expression HR (95 % CI) P-value β-catenin and
PROX expression
(HR 95 % CI) P-value
Low 1.00 Low 1.00 Low 1.00
High 0.54 (0.35–0.82) 0.004 High 0.63 (0.42–0.95) 0.026 Moderate 0.61 (0.36–1.03) 0.063
High 0.46 (0.28–0.76) 0.002
Abbreviations CI Confidence interval, HR Hazard ratio. Multivariate analysis included adjustment for age, gender, stage (IA-IIA, IIB and III) and lymph node ratio
(≥/< 20 %), postoperative adjuvant therapy, and perivascular invasion
Saukkonen et al. BMC Cancer  (2016) 16:472 Page 11 of 12
12. Qiao Q, Ramadani M, Gansauge S, Gansauge F, Leder G, Beger HG. Reduced
membranous and ectopic cytoplasmic expression of beta -catenin correlate
with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int
J Cancer. 2001;95(3):194–7.
13. Karayiannakis AJ, Syrigos KN, Polychronidis A, Simopoulos C. Expression
patterns of alpha-, beta- and gamma-catenin in pancreatic cancer:
correlation with E-cadherin expression, pathological features and prognosis.
Anticancer Res. 2001;21(6A):4127–34.
14. Wang Z. Aberrant Expression of CXCR4 and β-Catenin in Pancreatic Cancer.
Anticancer Res. 2013:1–8.
15. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C,
et al. Transcription factor PROX1 induces colon cancer progression by
promoting the transition from benign to highly dysplastic phenotype.
Cancer Cell. 2008;13(5):407–19.
16. Zinovieva RD, Duncan MK, Johnson TR, Torres R, Polymeropoulos MH,
Tomarev SI. Structure and chromosomal localization of the human
homeobox gene Prox 1. Genomics. 1996;35(3):517–22.
17. Kaltezioti V, Kouroupi G, Oikonomaki M, Mantouvalou E, Stergiopoulos A,
Charonis A, et al. Prox1 regulates the notch1-mediated inhibition of
neurogenesis. PLoS Biol. 2010;8(12):e1000565. Palmer TD, editor. Public
Library of Science.
18. Duncan MK, Cui W, Oh D-J, Tomarev SI. Prox1 is differentially localized
during lens development. Mech Dev. 2002;112(1–2):195–8.
19. Burke Z, Oliver G. Prox1 is an early specific marker for the developing liver and
pancreas in the mammalian foregut endoderm. Mech Dev. 2002;118(1–2):147–55.
20. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, et al. An
essential role for Prox1 in the induction of the lymphatic endothelial cell
phenotype. EMBO J. 2002;21(7):1505–13. EMBO Press.
21. Risebro CA, Searles RG, Melville AAD, Ehler E, Jina N, Shah S, et al. Prox1
maintains muscle structure and growth in the developing heart.
Development. 2009;136(3):495–505. The Company of Biologists Limited.
22. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or
consequence? Nat Rev Cancer. 2002;2(10):777–85.
23. Wiener Z, Högström J, Hyvönen V, Band AM, Kallio P, Holopainen T, et al.
Prox1 promotes expansion of the colorectal cancer stem cell population to
fuel tumor growth and ischemia resistance. Cell Rep. 2014;8(6):1943–56.
24. Elsir T, Eriksson A, Orrego A, Lindström MS, Nistér M. Expression of PROX1 Is a
common feature of high-grade malignant astrocytic gliomas. J Neuropathol
Exp Neurol. 2010;69(2):129–38.
25. Akagami M, Kawada K, Kubo H, Kawada M, Takahashi M, Kaganoi J, et al.
Transcriptional factor Prox1 plays an essential role in the antiproliferative
action of interferon-γ in esophageal cancer cells. Ann Surg Oncol. 2011;
18(13):3868–77.
26. Nagai H, Li Y, Hatano S, Toshihito O, Yuge M, Ito E, et al. Mutations and
aberrant DNA methylation of the PROX1 gene in hematologic malignancies.
Genes Chromosomes Cancer. 2003;38(1):13–21. Wiley Subscription Services,
Inc., A Wiley Company.
27. Versmold B, Felsberg J, Mikeska T, Ehrentraut D, Köhler J, Hampl JA, et al.
Epigenetic silencing of the candidate tumor suppressor gene PROX1 in
sporadic breast cancer. Int J Cancer. 2007;121(3):547–54. Wiley Subscription
Services, Inc., A Wiley Company.
28. Shimoda M, Takahashi M, Yoshimoto T, Kono T, Ikai I, Kubo H. A homeobox
protein, prox1, is involved in the differentiation, proliferation, and prognosis
in hepatocellular carcinoma. Clin Cancer Res. 2006;12(20 Pt 1):6005–11.
American Association for Cancer Research.
29. Schneider M, Büchler P, Giese N, Giese T, Wilting J, Büchler MW, et al. Role
of lymphangiogenesis and lymphangiogenic factors during pancreatic
cancer progression and lymphatic spread. Int J Oncol. 2006;28(4):883–90.
30. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, et al.
Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report
from the National Cancer Database. Cancer. 2007;110(4):738–44. Wiley
Subscription Services, Inc., A Wiley Company.
31. Wang J, Kilic G, Aydin M, Burke Z, Oliver G, Sosa-Pineda B. Prox1 activity
controls pancreas morphogenesis and participates in the production of
“secondary transition” pancreatic endocrine cells. Dev Biol. 2005;286(1):182–94.
32. Westmoreland JJ, Kilic G, Sartain C, Sirma S, Blain J, Rehg J, et al. Pancreas-
specific deletion of Prox1 affects development and disrupts homeostasis of
the exocrine pancreas. Gastroenterology. 2012;142(4):999–1009.e6.
33. Skog M, Bono P, Lundin M, Lundin J, Louhimo J, Linder N, et al. Expression
and prognostic value of transcription factor PROX1 in colorectal cancer. Br J
Cancer. 2011;105(9):1346–51.
34. Petrova TV, Mäkinen T, Mäkelä TP, Saarela J, Virtanen I, Ferrell RE, et al.
Lymphatic endothelial reprogramming of vascular endothelial cells by the
Prox-1 homeobox transcription factor. EMBO J. 2002;21(17):4593–9.
European Molecular Biology Organization.
35. Park Y-L, Myung E, Park S-Y, Kim N, Oak C-Y, Myung D-S, et al. Impact of
prospero homeobox-1 on tumor cell behavior and prognosis in colorectal
cancer. Am J Cancer Res. 2015;5(11):3286–300. e-Century Publishing Corporation.
36. Park K-J, Cho S-B, Park Y-L, Kim N, Park S-Y, Myung D-S, et al. Prospero
homeobox 1 mediates the progression of gastric cancer by inducing tumor
cell proliferation and lymphangiogenesis. Gastric Cancer. 2016;12.
37. Taban O, Cimpean AM, Raica M, Olariu S. PROX1 expression in gastric
cancer: from hypothesis to evidence. Anticancer Res. 2014;34(7):3439–46.
38. Choi D, Ramu S, Park E, Jung E, Yang S, Jung W, et al. Aberrant activation of
Notch signaling inhibits PROX1 activity to enhance the malignant behavior
of thyroid cancer cells. Cancer Res. 2015;canres.1199.2015. American
Association for Cancer Research
39. Joo Y-E, Rew J-S, Park C-S, Kim S-J. Expression of E-cadherin, alpha- and
beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology.
2002;2(2):129–37.
40. Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted
developmental biology of pancreatic ductal adenocarcinoma. Nat Rev
Cancer. 2010;10(10):683–95.
41. Yu EJ, Kim S-H, Kim HJ, Heo K, Ou C-Y, Stallcup MR, et al. Positive regulation
of β-catenin-PROX1 signaling axis by DBC1 in colon cancer progression.
Oncogene. 2015;19.
42. Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF-D,
Deshpande V, et al. Pancreatic ductal adenocarcinoma: is there a survival
difference for R1 resections versus locally advanced unresectable tumors?
What is a “true” R0 resection? Ann Surg. 2013;257(4):731–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Saukkonen et al. BMC Cancer  (2016) 16:472 Page 12 of 12
